

males and females (urban and rural) were calculated and Average Annual Percentage Changes (APC) were investigated.

Results: From 1970 to 2010 1 095 963 new cancer cases (547653 (49.98%) – in males and 548310 (50.02%) – in females) have been established in Belarus. In the analysis five main types of time-related ASR trends were distinguished. (1) Considerable decrease was shown in ASR of males and females stomach cancer as in lip cancer in males. (2) No considerable changes in ASR were detected for liver, pancreas, oesophagus, larynx, lung and bladder female cancers. (3) Constant growth of ASR was noted for colon cancer and melanoma of skin in both males and females and for breast, corpus uteri and renal female cancers. (4) ASR for female and male recto-sigmoidal cancer and male cancers of oesophagus, larynx, lung and bladder had been increasing till the middle of the 90s to be fixed at a certain level then. Thyroid cancer incidence jumped immediately after disaster from 0.45 in 1970th and 0.77 in 1986th to 3.2 in 2003^d (males) and from 0.81 in 1970th and 1.71 in 1986th to 14.9 in 2003^d (females). Since 2003^d morbidity has been flattened out both in males and females. The highest level of thyroid cancer incidence is noted in Mogilev, Gomel and Brest regions (most radiation contaminated). (5) Incidence rates for skin cancers in the both sexes, prostate and renal cancer in males slowly increasing from the 70s started growing rapidly in the middle of the 90s.

Conclusions: Despite of differences in structure and dynamics of cancer incidences in males and females the total number of new cancer cases was equal in both sexes. The above-mentioned ASR trends may be indicative of the impact of some environmental factors at certain periods of time which are modifying cancer incidence trends. Now we are working at cancer mapping through 118 administrative areas of Belarus to study mentioned above tendencies in details and propose some possible carcinogens to provide a basis for further analytical epidemiological studies.

3509

POSTER

Febrile Neutropenia Rates With Common Chemotherapy Regimens in Randomized Controlled Trials Compared With Non-randomized Cohort Studies – a Systematic Review and Meta-regression

C. Freedman¹, M. Trudeau¹, G. Tomlinson², K. Chan³. ¹Sunnybrook Odette Cancer Centre, Medical Oncology/Hematology, Toronto Ontario, Canada; ²University Health Network, Clinical Decision-making and Health Care, Toronto Ontario, Canada; ³Princess Margaret Hospital, Medical Oncology, Toronto Ontario, Canada

Background: Physicians commonly use febrile neutropenia (FN) rates from randomized controlled trials (RCTs) to decide on the need for primary prophylaxis (PP) with granulocyte colony-stimulating factor according to thresholds recommended by clinical guidelines. Patients in RCTs are highly selected, and their risk of FN may be lower than those from the unselected patient population. The FN rates from non-randomized cohort studies may be more generalisable to the unselected population.

Materials and Methods: A systematic review of all reported RCTs and non-randomized prospective and retrospective cohort studies was undertaken using Embase and Medline databases. Abstracts and journal articles published between 1996 and 2010 with recorded FN rates were included for breast, lung, and colorectal cancer chemotherapy regimens. Regimens were selected if there was at least one cohort study design and one RCT study design. Meta-regression, using logistic regression with random effects for each included study, was used to model the odds ratio (OR) of FN in non-randomized cohorts compared to RCT cohorts, adjusting for confounders.

Results: Based on 14 chemotherapy regimens and 101 publications, including 88 journal articles and 13 abstracts, 120 separate patient cohorts (49 from non-randomized cohort studies and 71 from RCTs) were included in the analysis. In total, 31,936 patients were analyzed and 2,538 had FN. The unadjusted FN rate of 15.83% (763/4,820) in the non-randomized cohorts was significantly higher than the rate of 6.55% (1,775/27,116) in the RCT cohorts (OR=2.33; 95% CI, 1.58 to 3.44; p = <0.001). Adjusting for regimen, publication vs. abstract, metastatic status, and age, the FN rate remained significantly higher in the non-randomized cohorts compared to the RCT cohorts (OR=1.69; 95% CI, 1.11 to 2.58; p = 0.035).

Conclusions: The RCT study design underestimates FN rates in breast, lung, and colorectal cancer patients compared to non-randomized cohort study designs, which may have better generalisability to the unselected patient population. Well designed population-based cohort studies are needed to determine the real world FN risk of chemotherapy regimens to guide the use of PP.

3510

POSTER

Low-carbohydrate, High-protein Score and Cancer Incidence and Mortality in a Northern Swedish Population

L. Nilsson¹, A. Winkvist², G. Hallmans¹, I. Johansson³, B. Lindahl¹, P. Lenner⁴, B. Van Guelpen⁵. ¹Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; ²Clinical Nutrition, University of Gothenburg, Gothenburg, Sweden; ³Odontology, Umeå University, Umeå, Sweden; ⁴Oncology and Radiation Sciences, Umeå University, Umeå, Sweden; ⁵Medical Biosciences, Umeå University, Umeå, Sweden

Background: Our purpose was to examine long-term effects of low-carbohydrate, high-protein (LCHP) diets in relation to cancer incidence and mortality in a large, population-based cohort.

Material and Methods: Baseline data from 36,660 men and 38,718 women in the population-based Västerbotten Intervention Program cohort were collected up to 18 years prior to cancer event (incident cancer and/or cancer death). Energy-adjusted descending deciles of carbohydrate and ascending deciles of protein intake were added to create an LCHP score (2–20 points). Sex-specific hazard ratios (HRs) for all-cause and site-specific cancer incidence and mortality were calculated by Cox regression analysis. Multivariate models were adjusted for age, body mass index, sedentary lifestyle, education, current smoking, and intake of alcohol, energy and saturated fat.

Results: A diet relatively low in carbohydrates and high in protein (LCHP score 14–20 points) was not associated with cancer incidence (number of cases = 3300) or mortality (number of deaths = 2503) in general in this population, compared to low LCHP scores (2–8 points). A tendency of a possible increased risk of incident endometrial cancer was noted in women with high versus low LCHP scores, in analyses limited to adequate energy reporters (number of cases = 42): multivariate HR 3.36, 95% CI 1.13–9.94, P for continuous = 0.070. Similarly, a tendency of a possible increased cancer mortality was found in 50-year-old women with high versus low LCHP scores (number of deaths = 170): multivariate HR: 1.38, 95% CI: 0.83–2.27; P for continuous = 0.074. Results were strengthened when HRs were calculated for LCHP scores based solely on animal protein, and attenuated when calculated on LCHP scores based solely on vegetable protein.

Conclusion: A diet relatively low in carbohydrates and high in protein does not generally predict altered risk of cancer incidence or mortality in this cohort. Further studies of long-term effects of LCHP in different age groups and in female cancer sites are warranted.

3511

POSTER

Epidemiology of Febrile Neutropenia

B.G. Doger de Spéville¹, M. Huelves Garcia¹, A. Lopez Gonzalez¹, P.J. Ibeas Millan¹, D. Perez Callejo¹, E. Almagro Casado¹, C. Maximiano Alonso¹, M. Mendez Garcia¹, B. Cantos Sanchez de Ibarguen¹, M. Provencio Pulla¹. ¹Hospital Puerta de Hierro, Medical Oncology, Madrid (Majadahonda), Spain

Background: Neutropenia is the most important risk factor for development of infections on the oncologic patients, and it is the main dose limiting toxicity and cause of delay on the administration of the anti-tumoral treatment, with a potential impact on the efficacy.

Febrile neutropenia must be suspected on patients with fever and discomfort who had received chemotherapy previously. In the 50% of those patients we can not demonstrate infection, 30% we can prove an infection, mainly bacterial, with microbiologic cultures and a clinical infection can be detected in almost 20%.

Material and Methods: This a retrospective study, we analyzed 87 patients with febrile neutropenia diagnosed on 1998, 2003 and 2008 at the Hospital Puerta de Hierro of Madrid, Spain.

The main objective was to determine if there was a difference on the micro-organism isolated on blood cultures in the last 10 years in these kind of patients. As secondary objectives we analyzed differences on chemotherapy schedules, degree of neutropenia, and antimicrobial treatment.

Results: 9 patients were excluded because of the lack of information because they did not achieved the inclusion criteria. 24 patients (30.8%) of the 78 included were diagnosed of febrile neutropenia on 1998, 41 patients (52.6%) on 2003, and 13 (16.7%) on 2008.

Blood cultures were obtained on 56 of the 78 patients included (71.8%), and we isolated any kind of bacteria on 16 (28.5%): 4 Gram negative (7.1%), 12 Gram positive (21.4%). On 26 patients (42.6%) we did not isolate any bacteria.

Conclusions: As published previously in our study the main group of bacteria isolated were Gram positive, mainly *S. aureus*, meanwhile there is a fall on the isolation of Gram negative during the last 10 years, with an important number of *P. aeruginosa* isolated in our hospital, main difference